The identification of a conserved α-helical domain in monkeypox virus H3 protein as critical for heparan sulfate binding unveils a novel therapeutic target, validated through AI and molecular dynamics simulations, offering potential for broad-spectrum antiviral development.

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

Enterovirus A71 adaptation to bind heparan sulfate as receptor comes with compensation that destabilizes its virus capsid.

The SARS-CoV-2 main protease specifically cleaves a conserved sequence in the human tRNA modifying enzyme TRMT1, resulting in reduced tRNA binding and the complete loss of TRMT1-mediated tRNA methyltransferase activity.